CPA Applauds Rubio-Miller Bill to Prohibit Chinese Companies from Receiving Inflation Reduction Act 45X Tax Credits
Congress must act to prohibit Chinese companies from receiving Inflation Reduction Act tax credits.
House China Select Committee Has Big Recommendations For Congress In 2024
The House China Select Committee released its 52 page strategy report for 2024. Here’s what’s inside, and what might be missing.
House China Committee Agrees On Key Principles, But Disagrees On Decoupling, Industrial Policy
In meeting about the new 2024 strategy report by the House Select Committee on the CCP, disagreements on decoupling, tariffs, and trade with China.
CPA Applauds House China Committee Report Calling for Revoking China’s MFN Status, Prohibiting CCP Companies from Exploiting U.S. Capital Markets
WASHINGTON — The Coalition for a Prosperous America (CPA) today applauded a new, bipartisan report released by the House Select Committee on the Strategic Competition
Katherine Tai Sticks Up For China Tariffs At Aspen Security Forum
Katherine Tai sticks up for domestic economy in international trade relations during Aspen Security Forum.
CPA, Law Enforcement, and Drug Advocacy Groups Urge Congress to Close De Minimis Loophole to Address Fentanyl Crisis
WASHINGTON — The Coalition for a Prosperous America (CPA), along with a coalition of law enforcement and national nonprofit and community-based organizations devoted to fighting
Senator Tillis Says U.S. Needs CHIPS Act for Generic Drugs in Short Supply
In Senate hearing: imported generic drugs facing consistent drug shortages need a government incentive program to help labs make life-saving commodity drugs domestically.
October Trade Deficit Up 5% As EU, Mexico Goods Gap Breaks 2022 Levels
The October trade deficit rose, but the biggest takeaway from the latest data is how much the China goods gap is in decline this year.
Is American Made Medication Preferred Over Imports?
A recent study suggests that Americans prefer locally produced medications if they are unclear where the product was made or if the lab has received bad reviews from an FDA inspection.
Investments in China: NC’s Patrick McHenry is Out of Step on this Issue
It should be a no-brainer to make sure that America’s investors don’t fund any of China’s military ambitions. And yet our very own Congressman, Patrick McHenry of North Carolina, is inexplicably blocking bipartisan congressional efforts to limit U.S. investments in China.